Allergy Therapeutics has strengthened its finances after raising £55 million from the exercise of 1.38 billion lender warrants, using the proceeds to fully repay its shareholder loan and clear all outstanding debt. The West Sussex-based MedTech, which develops allergy vaccines and immunotherapy treatments, said the move leaves it with a stronger balance sheet and more … Continue reading AIM-listed Allergy Therapeutics raises £55m & agrees loan facility